BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths CE, Jackson K, McHugh NJ. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161:987-1019. [PMID: 19857207 DOI: 10.1111/j.1365-2133.2009.09505.x] [Cited by in Crossref: 308] [Cited by in F6Publishing: 260] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Boehncke W, Katsambas A, Ortonne J, Puig L. EADV preceptorship: advances in dermatology: EADV preceptorship: advances in dermatology. Journal of the European Academy of Dermatology and Venereology 2010;24:2-24. [DOI: 10.1111/j.1468-3083.2010.03787.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Schulze-Koops H, Skapenko A. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm. Rheumatology (Oxford) 2017;56:iv30-48. [PMID: 28903543 DOI: 10.1093/rheumatology/kex277] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
3 Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016; 22(28): 6444-6455 [PMID: 27605880 DOI: 10.3748/wjg.v22.i28.6444] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
4 Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol 2014;170:986-7. [DOI: 10.1111/bjd.12713] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
5 Reid CT, De Gascun C, Hall W, Collins P, Lally A, Kirby B. Is universal screening for hepatitis C infection (HCV) prior to commencing anti-TNF-α therapy necessary? Br J Dermatol. 2013;Aug 21; Epub ahead of print. [PMID: 24032395 DOI: 10.1111/bjd.12598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Fonia A, Jackson K, Lereun C, Grant DM, Barker JN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010;163:807-16. [PMID: 20662837 DOI: 10.1111/j.1365-2133.2010.09944.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
7 Laws PM, Young HS. Current and emerging systemic treatment strategies for psoriasis. Drugs 2012;72:1867-80. [PMID: 22938141 DOI: 10.2165/11634980-000000000-00000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
8 Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, Mamolo C. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol 2016;30:1753-9. [PMID: 27271195 DOI: 10.1111/jdv.13702] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
9 Kim WB, Marinas JE, Qiang J, Shahbaz A, Greaves S, Yeung J. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study. J Am Acad Dermatol 2015;73:237-41. [PMID: 26026334 DOI: 10.1016/j.jaad.2015.04.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
10 Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther 2015;28:390-403. [PMID: 26258910 DOI: 10.1111/dth.12267] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
11 Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013;13:1715-1730. [PMID: 24160990 DOI: 10.1517/14712598.2013.853739] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
12 Riveros BS, Ziegelmann PK, Correr CJ. Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective. Value in Health Regional Issues 2014;5:65-72. [DOI: 10.1016/j.vhri.2014.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Laws PM, Young HS. Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol 2010;3:25-37. [PMID: 21437057 DOI: 10.2147/ccid.s6497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
14 Prasad Hunasehally R, Anstey A. Review of the 90th Annual Meeting of the British Association of Dermatologists, 6-8 July 2010, Manchester, U.K.: British Association of Dermatologists 90th Annual Meeting. British Journal of Dermatology 2011;164:712-9. [DOI: 10.1111/j.1365-2133.2011.10294.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Patton T, Bojke L, Walton M, Manca A, Helliwell P. Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries? Clin Rheumatol 2017;36:1803-10. [PMID: 28612241 DOI: 10.1007/s10067-017-3703-9] [Reference Citation Analysis]
16 Abdulghani M, Al Sheik A, Alkhawajah M, Ammoury A, Behrens F, Benchikhi H, Benkaidali I, Doss N, El Gendy A, Mokhtar I, Odendaal D, Raboobee N, Thaçi D, Weiss R, Whitaker D. Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement. J Int Med Res 2011;39:1573-88. [PMID: 22117959 DOI: 10.1177/147323001103900501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012;26:1331-44. [PMID: 22404617 DOI: 10.1111/j.1468-3083.2012.04492.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
18 Puig L, Carrascosa J, Carretero G, de la Cueva P, Lafuente-urrez R, Belinchón I, Sánchez-regaña M, García-bustínduy M, Ribera M, Alsina M, Ferrándiz C, Fonseca E, García-patos V, Herrera E, Estebaranz JL, Marrón S, Moreno J, Notario J, Rivera R, Rodriguez-cerdeira C, Romero A, Ruiz-villaverde R, Taberner R, Vidal D. Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento. Actas Dermo-Sifiliográficas 2013;104:694-709. [DOI: 10.1016/j.ad.2013.04.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
19 Chen Y, Wu C, Shen J, Chen T, Chang Y. Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: Results of a nationwide cohort study from Taiwan. Journal of the American Academy of Dermatology 2013;69:25-33. [DOI: 10.1016/j.jaad.2012.12.966] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
20 Tausend W, Downing C, Tyring S. Systematic Review of Interleukin-12, Interleukin-17, and Interleukin-23 Pathway Inhibitors for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis: Ustekinumab, Briakinumab, Tildrakizumab, Guselkumab, Secukinumab, Ixekizumab, and Brodalumab. J Cutan Med Surg 2014;18:156-69. [DOI: 10.2310/7750.2013.13125] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
21 Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, Erickson J, Zhang L, Mallbris L, Gerdes S. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J Eur Acad Dermatol Venereol 2017;31:679-85. [PMID: 27696577 DOI: 10.1111/jdv.13990] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
22 Mrowietz U, de Jong EM, Kragballe K, Langley R, Nast A, Puig L, Reich K, Schmitt J, Warren RB. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2014;28:438-53. [PMID: 23437792 DOI: 10.1111/jdv.12118] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
23 Puig L, Fan T, Ding Q, Smith NE. Predictors of biologic treatment of psoriasis: a non-interventional study. Clinicoecon Outcomes Res 2014;6:93-100. [PMID: 24600238 DOI: 10.2147/CEOR.S54797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Atwan A, Abbott R, Kelly MJ, Pickles T, Bauer A, Taylor C, Piguet V, Ingram JR, Ingram JR. Oral fumaric acid esters for psoriasis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd010497] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Honma M, Shibuya T, Iwasaki T, Iinuma S, Takahashi N, Kishibe M, Minami-Hori M, Ishida-Yamamoto A. Prevalence of coronary artery calcification in Japanese patients with psoriasis: A close correlation with bilateral diagonal earlobe creases. J Dermatol 2017;44:1122-8. [PMID: 28464401 DOI: 10.1111/1346-8138.13895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
26 Davison N, Warren R, Mason K, Mcelhone K, Kirby B, Burden A, Smith C, Payne K, Griffiths C. Identification of factors that may influence the selection of first‐line biological therapy for people with psoriasis: a prospective, multicentre cohort study. Br J Dermatol 2017;177:828-36. [DOI: 10.1111/bjd.15551] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
27 Ramos JM, Masiá M, Rodríguez JC, López C, Padilla S, Robledano C, Navarro-blasco FJ, Matarredona J, García-sepulcre MF, Gutiérrez F. Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases. Clin Exp Med 2013;13:177-86. [DOI: 10.1007/s10238-012-0192-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
28 Fotiadou C, Lazaridou E, Ioannides D. Management of psoriasis in adolescence. Adolesc Health Med Ther 2014;5:25-34. [PMID: 24729738 DOI: 10.2147/AHMT.S36672] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 4.1] [Reference Citation Analysis]
29 Thaçi D, Ortonne J, Chimenti S, Ghislain P, Arenberger P, Kragballe K, Saurat J, Khemis A, Sprøgel P, Esslinger H, Unnebrink K, Kupper H. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study: Adalimumab and topical treatment in psoriasis. British Journal of Dermatology 2010;163:402-11. [DOI: 10.1111/j.1365-2133.2010.09791.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 7.3] [Reference Citation Analysis]
30 Woolf RT, Smith CH, Robertson K, Barker JN. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. Br J Dermatol 2010;163:889-92. [PMID: 20854408 DOI: 10.1111/j.1365-2133.2010.09893.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
31 Martyn-simmons C, Mee J, Kirkham B, Groves R, Milburn H. Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis -specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional study: Evaluation of IGRA for screening of TB infection. Br J Dermatol 2013;168:1012-8. [DOI: 10.1111/bjd.12176] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
32 De Mozzi P, Johnston G, Alexandroff A. Psoriasis: an evidence-based update. Report of the 9th Evidenced Based Update Meeting, 12 May 2011, Loughborough, U.K.: Report of the 9th Evidence Based Update Meeting on psoriasis. British Journal of Dermatology 2012;166:252-60. [DOI: 10.1111/j.1365-2133.2011.10767.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Lopes LC, Silveira MS, Camargo IA, Barberato-Filho S, Del Fiol Fde S, Osorio-de-Castro CG. Biological drugs for the treatment of psoriasis in a public health system. Rev Saude Publica 2014;48:651-61; discussion 661. [PMID: 25210824 DOI: 10.1590/s0034-8910.2014048005109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
34 Chat VS, Uppal SK, Kearns DG, Wu JJ. Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review. Dermatol Ther 2021;34:e14974. [PMID: 33991048 DOI: 10.1111/dth.14974] [Reference Citation Analysis]
35 Wee JS, Petrof G, Jackson K, Barker JN, Smith CH. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. Br J Dermatol 2012;167:411-6. [PMID: 22404545 DOI: 10.1111/j.1365-2133.2012.10931.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
36 Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs 2014;74:1379-410. [PMID: 25034360 DOI: 10.1007/s40265-014-0258-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
37 Hägg D, Sundström A, Eriksson M, Schmitt-egenolf M. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). J Eur Acad Dermatol Venereol 2015;29:452-6. [DOI: 10.1111/jdv.12576] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
38 Ormerod AD. Switching biologics for psoriasis. Br J Dermatol 2010;163:667-9. [PMID: 20854399 DOI: 10.1111/j.1365-2133.2010.09999.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
39 Rustin M. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data: Long-term safety of biologics for moderate-to-severe plaque psoriasis. British Journal of Dermatology 2012;167:3-11. [DOI: 10.1111/j.1365-2133.2012.11208.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 7.2] [Reference Citation Analysis]
40 Bracke S, Lambert J. Viewpoint on handling anti-TNF failure in psoriasis. Arch Dermatol Res 2013;305:945-50. [PMID: 24096701 DOI: 10.1007/s00403-013-1418-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
41 Rajagopalan M, Mital A. Biologics use in Indian psoriasis patients. Indian Dermatol Online J 2016;7:489-97. [PMID: 27990383 DOI: 10.4103/2229-5178.193915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
42 Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhal R, Reich K. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2021. [PMID: 34652810 DOI: 10.1111/bjd.20818] [Reference Citation Analysis]
43 Kemeny L, Amaya M, Cetkovska P, Rajatanavin N, Lee WR, Szumski A, Marshall L, Mahgoub EY, Aldinç E. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial. BMC Dermatol 2015;15:9. [PMID: 25994179 DOI: 10.1186/s12895-015-0028-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
44 Puig L, de la Cueva P, Linares M, Suarez J, Velasco M, Vidal D, Zulaica A, García-Calvo C. Expert report on psoriasis: Spanish dermatologists' opinions on the use of biologic agents to manage moderate to severe psoriasis in adults. Actas Dermosifiliogr 2013;104:400-8. [PMID: 23669590 DOI: 10.1016/j.adengl.2013.04.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 2012;167:180-90. [PMID: 22413944 DOI: 10.1111/j.1365-2133.2012.10941.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 10.6] [Reference Citation Analysis]
46 Gladman DD, Poulin Y, Adams K, Bourcier M, Barac S, Barber K, Chandran V, Dutz J, Flanagan C, Gooderham MJ, Gulliver WP, Ho VC, Hong C, Karsh J, Khraishi MM, Lynde CW, Papp KA, Rahman P, Rohekar S, Rosen CF, Russell AS, Vender RB, Yeung J, Ziouzina O, Zummer M. Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. J Rheumatol 2017;44:519-34. [DOI: 10.3899/jrheum.161473] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
47 Dawe R. There are no ‘safe exposure limits’ for phototherapy. British Journal of Dermatology 2010;163:209-10. [DOI: 10.1111/j.1365-2133.2010.09746.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Signorovitch J, Betts K, Yan Y, Lereun C, Sundaram M, Wu E, Mulani P. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. Br J Dermatol 2015;172:504-12. [DOI: 10.1111/bjd.13437] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 8.5] [Reference Citation Analysis]
49 van Lümig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC, Fransen J, Kievit W, de Jong EM. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol 2015;29:752-60. [PMID: 25229823 DOI: 10.1111/jdv.12675] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
50 Goujon C, Bachelez H; Groupe de recherche sur le psoriasis de la Société française de dermatologie. [Infliximab]. Ann Dermatol Venereol 2019;146:483-6. [PMID: 31230775 DOI: 10.1016/j.annder.2019.04.013] [Reference Citation Analysis]
51 Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP. Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol 2012;132:76-84. [PMID: 21881588 DOI: 10.1038/jid.2011.238] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
52 Lunder T, Marko P, Koser Kolar N, Kralj B, Kecelj Leskovec N. Drug survival of biologic therapies for the treatment of psoriasis: Results of Slovenian national registry. Biologicals 2018;54:44-9. [PMID: 29706309 DOI: 10.1016/j.biologicals.2018.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
53 Woolf RT, Smith CH. How genetic variation affects patient response and outcome to therapy for psoriasis. Expert Rev Clin Immunol 2010;6:957-66. [PMID: 20979559 DOI: 10.1586/eci.10.74] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
54 Daudén E, Puig L, Ferrándiz C, Sánchez-Carazo JL, Hernanz-Hermosa JM; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 2016;30 Suppl 2:1-18. [PMID: 26812550 DOI: 10.1111/jdv.13542] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 13.2] [Reference Citation Analysis]
55 Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen Møller A. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. J Dermatolog Treat 2018;29:557-68. [PMID: 29323542 DOI: 10.1080/09546634.2018.1427205] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
56 Ponnambath N, Kalavala M, Anstey AV, Piguet V, Ingram JR. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20. Clin Exp Dermatol 2016;41:95-6. [DOI: 10.1111/ced.12651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Guerra I, Algaba A, Pérez-Calle JL, Chaparro M, Marín-Jiménez I, García-Castellanos R, González-Lama Y, López-Sanromán A, Manceñido N, Martínez-Montiel P, Quintanilla E, Taxonera C, Villafruela M, Romero-Maté A, López-Serrano P, Gisbert JP, Bermejo F. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2012;6:518-23. [PMID: 22398059 DOI: 10.1016/j.crohns.2011.10.007] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 5.7] [Reference Citation Analysis]
58 Lopes LC, Silveira MSDN, de Camargo MC, de Camargo IA, Luz TCB, Osorio-de-castro CGS, Barberato-filho S, Del Fiol FDS, Guyatt G. Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil. Expert Opinion on Drug Safety 2014;13:1155-63. [DOI: 10.1517/14740338.2014.942219] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
59 Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, Puppo F. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opinion on Drug Safety 2019;18:219-29. [DOI: 10.1080/14740338.2019.1577817] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
60 Ohtsuki M, Morita A, Igarashi A, Imafuku S, Tada Y, Fujita H, Fujishige A, Yamaguchi M, Teshima R, Tani Y, Nakagawa H. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. J Dermatol 2017;44:1105-11. [PMID: 28543617 DOI: 10.1111/1346-8138.13911] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
61 Poór AK, Brodszky V, Péntek M, Gulácsi L, Ruzsa G, Hidvégi B, Holló P, Kárpáti S, Sárdy M, Rencz F. Is the DLQI appropriate for medical decision-making in psoriasis patients? Arch Dermatol Res 2018;310:47-55. [PMID: 29128966 DOI: 10.1007/s00403-017-1794-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
62 Laws PM, Warren RB. Ustekinumab for the treatment of psoriasis. Expert Review of Clinical Immunology 2014;7:155-64. [DOI: 10.1586/eci.11.4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
63 Krakowski P, Gerkowicz A, Pietrzak A, Krasowska D, Jurkiewicz A, Gorzelak M, Schwartz RA. Psoriatic arthritis - new perspectives. Arch Med Sci 2019;15:580-9. [PMID: 31110522 DOI: 10.5114/aoms.2018.77725] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
64 Ormerod AD, Augustin M, Baker C, Chosidow O, Cohen AD, Dam TN, Garcia-Doval I, Lecluse LL, Schmitt-Egenolf M, Spuls PI. Challenges for synthesising data in a network of registries for systemic psoriasis therapies. Dermatology. 2012;224:236-243. [PMID: 22678413 DOI: 10.1159/000338572] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
65 Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH, Reynolds NJ, Griffiths CEM. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. Br J Dermatol 2017;177:1410-21. [PMID: 28369707 DOI: 10.1111/bjd.15531] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
66 Roubille C, Richer V, Starnino T, Mccourt C, Mcfarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B. Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J Rheumatol 2015;42:1767-80. [DOI: 10.3899/jrheum.141112] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 12.7] [Reference Citation Analysis]
67 Hasan T, Au E, Chen S, Tong A, Wong G. Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open 2018;8:e022445. [PMID: 30209157 DOI: 10.1136/bmjopen-2018-022445] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
68 Papp K, Menter M, Abe M, Elewski B, Feldman S, Gottlieb A, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; the OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015;173:949-61. [DOI: 10.1111/bjd.14018] [Cited by in Crossref: 173] [Cited by in F6Publishing: 151] [Article Influence: 28.8] [Reference Citation Analysis]
69 Chalmers RJ. Assessing Psoriasis Severity and Outcomes for Clinical Trials and Routine Clinical Practice. Dermatologic Clinics 2015;33:57-71. [DOI: 10.1016/j.det.2014.09.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
70 Khalid JM, Fox KM, Globe G, Maguire A, Chau D. Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England. Journal of Dermatological Treatment 2013;25:67-72. [DOI: 10.3109/09546634.2013.768762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
71 Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: A comprehensive literature review. World J Gastroenterol 2013; 19(44): 7867-7873 [PMID: 24307780 DOI: 10.3748/wjg.v19.i44.7867] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 50] [Article Influence: 7.9] [Reference Citation Analysis]
72 Griffiths CEM, Barker JNWN. Psoriasis. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell; 2010. pp. 1-60. [DOI: 10.1002/9781444317633.ch20] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
73 Kurtovic NO, Halilovic EK. Serum Concentrations of Interferon Gamma (IFN-γ) in Patients with Psoriasis: Correlation with Clinical Type and Severity of the Disease. Med Arch 2018;72:410-3. [PMID: 30814771 DOI: 10.5455/medarh.2018.72.410-413] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
74 Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess 2017;21:1-326. [PMID: 28976302 DOI: 10.3310/hta21560] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
75 Thompson C, Davies R, Choy E. Anti cytokine therapy in chronic inflammatory arthritis. Cytokine 2016;86:92-9. [DOI: 10.1016/j.cyto.2016.07.015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
76 van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai T, Gong Y, Huang J, Papavassilis C, Fox T. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology 2016;75:83-98.e4. [DOI: 10.1016/j.jaad.2016.03.024] [Cited by in Crossref: 182] [Cited by in F6Publishing: 159] [Article Influence: 36.4] [Reference Citation Analysis]
77 Yang Y, Kang J, Lin H. Increased risk of psoriasis following obstructive sleep apnea: A longitudinal population-based study. Sleep Medicine 2012;13:285-9. [DOI: 10.1016/j.sleep.2011.07.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
78 Hu Y, Chen Z, Gong Y, Shi Y. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis. Clin Drug Investig 2018;38:191-9. [PMID: 29249053 DOI: 10.1007/s40261-017-0603-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
79 Gulliver W, Lynde C, Dutz JP, Vender RB, Yeung J, Bourcier M, Dion P, Hong C, Searles G, Poulin Y. Think beyond the Skin: 2014 Canadian Expert Opinion Paper on Treating to Target in Plaque Psoriasis. J Cutan Med Surg 2015;19:22-7. [DOI: 10.2310/7750.2014.13151] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
80 AbuHilal M, Ho N. Successful treatment of severe psoriasis in an adolescent with ustekinumab. Pediatr Dermatol 2015;32:377-80. [PMID: 25727845 DOI: 10.1111/pde.12545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
81 de Camargo MC, Barros BCA, Fulone I, Silva MT, Silveira MSDN, de Camargo IA, Barberato-Filho S, Del Fiol FS, Lopes LC. Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting. Front Pharmacol 2019;10:965. [PMID: 31572173 DOI: 10.3389/fphar.2019.00965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
82 Vaidya B, Nakarmi S. Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal. Int J Rheumatol 2019;2019:2034950. [PMID: 31057626 DOI: 10.1155/2019/2034950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Ali F, Cueva A, Vyas J, Atwan A, Salek M, Finlay A, Piguet V. A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol 2017;176:577-93. [DOI: 10.1111/bjd.14788] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
84 Hackett C, Kirby B. Primary varicella-zoster infection in patients on biologic therapies for psoriasis. British Journal of Dermatology 2010;163:1122-1122. [DOI: 10.1111/j.1365-2133.2010.09938.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
85 Ighani A, Georgakopoulos JR, Yeung J. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. G Ital Dermatol Venereol 2020;155:400-10. [PMID: 32348084 DOI: 10.23736/S0392-0488.20.06643-2] [Reference Citation Analysis]
86 Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010;160:810-20. [PMID: 20590580 DOI: 10.1111/j.1476-5381.2010.00702.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 8.2] [Reference Citation Analysis]
87 Asahina A, Ishii N, Tohma S. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis: Letters to the Editor. The Journal of Dermatology 2012;39:199-201. [DOI: 10.1111/j.1346-8138.2011.01243.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
88 Richter L, Vujic I, Sesti A, Monshi B, Sanlorenzo M, Posch C, Rappersberger K. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. J Dtsch Dermatol Ges 2017;15:309-17. [PMID: 28240404 DOI: 10.1111/ddg.13191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
89 Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, Gelfand JM. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol 2014;71:633-41. [PMID: 24928705 DOI: 10.1016/j.jaad.2014.05.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
90 Sadlier M, Sadlier C, Alani A, Ahmad K, Bergin C, Ramsay B. Poor adherence to vaccination guidelines in dermatology patients on immunosuppressive therapies: an issue that needs addressing. Br J Dermatol 2015;173:288-9. [PMID: 25400075 DOI: 10.1111/bjd.13543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Parker S, Zhang AL, Zhang CS, Goodman G, Wen Z, Lu C, Xue CC. Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial. Trials 2014;15:495. [PMID: 25526951 DOI: 10.1186/1745-6215-15-495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
92 Tham L, Tang C, Choi S, Satterwhite JH, Cameron GS, Banerjee S. Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis: The Journal of Clinical Pharmacology. The Journal of Clinical Pharmacology 2014;54:1117-24. [DOI: 10.1002/jcph.312] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
93 Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat 2013;24:64-9. [PMID: 21797808 DOI: 10.3109/09546634.2011.607425] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
94 Kanelleas A, Liapi C, Katoulis A, Stavropoulos P, Avgerinou G, Georgala S, Economopoulos T, Stavrianeas NG, Katsambas A. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol. 2011;36:845-850. [PMID: 21790728 DOI: 10.1111/j.1365-2230.2011.04131.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
95 Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. Journal of Dermatological Treatment 2015;26:23-31. [DOI: 10.3109/09546634.2013.865009] [Cited by in Crossref: 104] [Cited by in F6Publishing: 81] [Article Influence: 13.0] [Reference Citation Analysis]
96 Viguier M, Pagès C, Aubin F, Delaporte E, Descamps V, Lok C, Beylot-barry M, Séneschal J, Dubertret L, Morand J, Dréno B, Bachelez H; for the Groupe Français de Recherche sur le Psoriasis. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study: Biologics in erythrodermic psoriasis. British Journal of Dermatology 2012;167:417-23. [DOI: 10.1111/j.1365-2133.2012.10940.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
97 Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N. Systemic Treatment of Pediatric Psoriasis: A Review. Dermatol Ther (Heidelb) 2016;6:125-42. [PMID: 27085539 DOI: 10.1007/s13555-016-0117-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
98 Amerio P, Amoruso G, Bardazzi F, Campanati A, Cassano N, Conti A, Gisondi P, Guarneri C, Mazzotta A, Piaserico S, Prestinari F, Prignano F, Zane C, de Simone C. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. Journal of Dermatological Treatment 2013;24:305-11. [DOI: 10.3109/09546634.2011.654107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
99 Griffiths C, Sterry W, Brock F, Dilleen M, Stefanidis D, Germain J, Mallbris L. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. Br J Dermatol 2015;172:230-8. [DOI: 10.1111/bjd.13139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
100 Sánchez-moya A, Daudén E. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts: Correspondence. British Journal of Dermatology 2011;164:208-9. [DOI: 10.1111/j.1365-2133.2010.10028.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
101 Morais MR, Meneghello LP, de Oliveira CF, Carvalho AV. Late reaction to ustekinumab infusion. Dermatol Reports 2013;5:e2. [PMID: 25386321 DOI: 10.4081/dr.2013.e2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
102 Alsharqi A, Parslew R, Dever B, Arslanian V. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?: Letter to the Editor. Australasian Journal of Dermatology 2012;53:e45-6. [DOI: 10.1111/j.1440-0960.2012.00891.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Sterry W, van de Kerkhof P. Is ‘class effect’ relevant when assessing the benefit/risk profile of a biologic agent?: Is ‘class effect’ relevant when assessing the benefit/risk profile of a biologic agent? Journal of the European Academy of Dermatology and Venereology 2012;26:9-16. [DOI: 10.1111/j.1468-3083.2012.04605.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
104 Puig L, de la Cueva P, Linares M, Suarez J, Velasco M, Vidal D, Zulaica A, García-calvo C. Informe de expertos en psoriasis: opinión de los dermatólogos españoles sobre el manejo de la psoriasis moderada-grave con agentes biológicos en pacientes adultos. Actas Dermo-Sifiliográficas 2013;104:400-8. [DOI: 10.1016/j.ad.2012.10.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
105 Mercuri SR, Naldi L. Potential role of ustekinumab in the treatment of chronic plaque psoriasis. Biologics 2010;4:119-29. [PMID: 20531968 DOI: 10.2147/btt.s4921] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
106 Liu M, Huang YYM, Hsu S, Kass JS. Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications. CNS Drugs 2016;30:1149-68. [DOI: 10.1007/s40263-016-0392-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
107 Hajjaj FM, Salek MS, Basra MK, Finlay AY. Nonclinical influences, beyond diagnosis and severity, on clinical decision making in dermatology: understanding the gap between guidelines and practice. Br J Dermatol 2010;163:789-99. [PMID: 20854402 DOI: 10.1111/j.1365-2133.2010.09868.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
108 Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. Journal of the American Academy of Dermatology 2012;66:241-51. [DOI: 10.1016/j.jaad.2010.12.005] [Cited by in Crossref: 108] [Cited by in F6Publishing: 85] [Article Influence: 12.0] [Reference Citation Analysis]
109 Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, Papay P, Allez M, Cosnes J, Cortot A. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-1055. [PMID: 20728573 DOI: 10.1016/j.cgh.2010.07.022] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 10.0] [Reference Citation Analysis]
110 Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. J Med Econ 2018;21:810-20. [PMID: 29873270 DOI: 10.1080/13696998.2018.1474747] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
111 Matsumoto A, Komine M, Karakawa M, Kishimoto M, Ohtsuki M. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol 2017;44:202-4. [DOI: 10.1111/1346-8138.13632] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
112 Plachouri KM, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat 2019;30:668-73. [PMID: 30428753 DOI: 10.1080/09546634.2018.1544413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
113 Takeshita J, Armstrong AW, Mease PJ, Gelfand JM. Treat-to-target and Improving Outcomes in Psoriasis: A Report from the GRAPPA 2014 Annual Meeting. J Rheumatol 2015;42:1037-40. [DOI: 10.3899/jrheum.150128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther 2015;28:179-93. [PMID: 26201310 DOI: 10.1111/dth.12251] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
115 Racz E, Prens EP. Phototherapy and photochemotherapy for psoriasis. Dermatol Clin 2015;33:79-89. [PMID: 25412785 DOI: 10.1016/j.det.2014.09.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
116 Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. J Dermatolog Treat 2013;24:38-49. [PMID: 22268700 DOI: 10.3109/09546634.2012.660520] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
117 Karamata VV, Gandhi AM, Patel PP, Sutaria A, Desai MK. A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life. Indian J Pharmacol 2017;49:84-8. [PMID: 28458428 DOI: 10.4103/ijp.IJP_166_16] [Reference Citation Analysis]
118 Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2015;73:420-428.e1. [PMID: 26184440 DOI: 10.1016/j.jaad.2015.06.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
119 Hamadah IR, Al Raddadi AA, Bahamdan KA, Fatani MI, Alnahdi A, Al Rakban AM, Alkhalifah A, Al Ameer A, Shaikh YH, Elgendi AM, Al Zoman AY, Alafif KA. Saudi practical guidelines on biologic treatment of psoriasis. J Dermatolog Treat 2015;26:223-9. [PMID: 25075955 DOI: 10.3109/09546634.2014.946882] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
120 Feighery C, Dunne J, Bingham EA, Feighery CF. Evaluation of soluble CD163 as a marker of inflammation in psoriasis: Evaluation of soluble CD163 as a marker of inflammation in psoriasis. Clinical and Experimental Dermatology 2011;36:201-3. [DOI: 10.1111/j.1365-2230.2010.03949.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
121 Chen X, Cheng Y, Yang M, Liu GJ, Zhang M, Zhang M. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd009481] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
122 Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol 2017;76:393-403. [PMID: 28212760 DOI: 10.1016/j.jaad.2016.07.065] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 18.5] [Reference Citation Analysis]
123 Griffiths CE. Biologics for psoriasis: current evidence and future use. Br J Dermatol 2012;167 Suppl 3:1-2. [PMID: 23082809 DOI: 10.1111/j.1365-2133.2012.11207.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
124 Karlsson-Groth A, Rystedt A, Swartling C. Treatment of compensatory hyperhidrosis after sympathectomy with botulinum toxin and anticholinergics. Clin Auton Res 2015;25:161-7. [PMID: 25773586 DOI: 10.1007/s10286-015-0278-x] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
125 Boros M, Kemény Á, Sebők B, Bagoly T, Perkecz A, Petőházi Z, Maász G, Schmidt J, Márk L, László T, Helyes Z, Szolcsányi J, Pintér E. Sulphurous medicinal waters increase somatostatin release: It is a possible mechanism of anti-inflammatory effect of balneotherapy in psoriasis. European Journal of Integrative Medicine 2013;5:109-18. [DOI: 10.1016/j.eujim.2012.09.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
126 Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis – best use of biologics. Expert Review of Clinical Immunology 2014;10:269-79. [DOI: 10.1586/1744666x.2014.873701] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
127 Guerra I, Gisbert JP. Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents. Expert Rev Gastroenterol Hepatol. 2013;7:41-48. [PMID: 23265148 DOI: 10.1586/egh.12.64] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
128 Atakan N, Yazici AC, Özarmağan G, İnalÖz HS, Gürer MA, Sabuncu İ, Kİremİtçİ Ü, Alper S, Aytekİn S, Arican Ö, Polat M, Doğan S, Aldİnç E. TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey. J Dermatol 2016;43:298-304. [PMID: 26365805 DOI: 10.1111/1346-8138.13081] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
129 Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A; International Psoriasis Council Board Members and Councilors. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol 2020;82:117-22. [PMID: 31425723 DOI: 10.1016/j.jaad.2019.08.026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
130 Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis: Treatment goals for the long-term management of psoriasis. Journal of the European Academy of Dermatology and Venereology 2012;26:12-20. [DOI: 10.1111/j.1468-3083.2011.04411.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
131 Fonseca E, Iglesias R, Paradela S, Fernández-Torres RM, Elberdín L. Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting. J Dermatolog Treat 2015;26:217-22. [PMID: 24920071 DOI: 10.3109/09546634.2014.933166] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
132 Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67:1349-1361. [PMID: 22727462 DOI: 10.1016/j.jaad.2012.04.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
133 Shah VV, Lee EB, Reddy S, Lin EJ, Wu JJ. Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review. J Dermatolog Treat 2018;29:586-92. [PMID: 29334280 DOI: 10.1080/09546634.2018.1428723] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
134 Torbica A, Fattore G, Ayala F. Eliciting preferences to inform patient-centred policies: the case of psoriasis. Pharmacoeconomics 2014;32:209-23. [PMID: 24446282 DOI: 10.1007/s40273-013-0126-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
135 Wheeler T. Psoriasis: impact and management of moderate to severe disease. British Journal of Nursing 2010;19:10-7. [DOI: 10.12968/bjon.2010.19.1.45905] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
136 Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review. Am J Clin Dermatol 2014;15:37-43. [PMID: 24281790 DOI: 10.1007/s40257-013-0053-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
137 Wu JJ, Guérin A, Gauthier G, Sundaram M. Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. J Dermatolog Treat 2017;28:290-8. [PMID: 27783534 DOI: 10.1080/09546634.2016.1247946] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
138 Laws P, Downs A, Parslew R, Dever B, Smith C, Barker J, Moriarty B, Murphy R, Kirby B, Burden A, Mcbride S, Anstey A, O’shea S, Ralph N, Buckley C, Griffiths C, Warren R. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland: Practical experience of ustekinumab in the treatment of psoriasis. British Journal of Dermatology 2012;166:189-95. [DOI: 10.1111/j.1365-2133.2011.10638.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
139 Sacchelli L, Magnano M, Loi C, Patrizi A, Bardazzi F. The unforeseen during biotechnological therapy for moderate-to-severe psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering. Dermatol Ther 2020;33:e13411. [PMID: 32291848 DOI: 10.1111/dth.13411] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, Van Voorhees AS, Armstrong AW, Siegel M, Wu JJ. From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology 2016;75:798-805.e7. [DOI: 10.1016/j.jaad.2016.06.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
141 Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10 Suppl 2:S1-95. [PMID: 22386073 DOI: 10.1111/j.1610-0387.2012.07919.x] [Cited by in Crossref: 181] [Cited by in F6Publishing: 147] [Article Influence: 20.1] [Reference Citation Analysis]
142 Johansson E, Nuñez M, Svedbom A, Dilla T, Hartz S. Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain. Clinicoecon Outcomes Res 2018;10:747-59. [PMID: 30519064 DOI: 10.2147/CEOR.S167727] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
143 Silveira MS, de Camargo IA, Osorio-de-Castro CG, Barberato-Filho S, Del Fiol Fde S, Guyatt G, de Camargo MC, Lopes LC. Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil. BMJ Open 2014;4:e004179. [PMID: 24598304 DOI: 10.1136/bmjopen-2013-004179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
144 Bachelez H. [Pustular psoriasis]. Ann Dermatol Venereol 2012;139 Suppl 2:S34-8. [PMID: 22541726 DOI: 10.1016/S0151-9638(12)70108-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Di Renzo L, Bianchi A, Saraceno R, Calabrese V, Cornelius C, Iacopino L, Chimenti S, De Lorenzo A. -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers. Pharmacogenet Genomics 2012;22:134-42. [PMID: 22158445 DOI: 10.1097/FPC.0b013e32834e5e7b] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
146 Stevenson ML, Lebwohl M. Iatrogenic effects of biologics for psoriasis. Clin Dermatol 2011;29:614-21. [PMID: 22014983 DOI: 10.1016/j.clindermatol.2011.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
147 Ohtsuki M, Terui T, Ozawa A, Morita A, Sano S, Takahashi H, Komine M, Etoh T, Igarashi A, Torii H. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013;40:683-695. [PMID: 24033880 DOI: 10.1111/1346-8138.12239] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
148 Sarkar S, Panda S, Kim B, Raychaudhuri SK, Ghosh A, Raychaudhuri SP. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population. Indian J Dermatol Venereol Leprol 2020;86:1-7. [PMID: 31719235 DOI: 10.4103/ijdvl.IJDVL_791_18] [Reference Citation Analysis]
149 Ingram JR, Anstey AV, Piguet V. Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis? Br J Dermatol 2012;167:949-51. [PMID: 22486276 DOI: 10.1111/j.1365-2133.2012.10983.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
150 Mrowietz U, Kragballe K, Nast A, Reich K. Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting. J Eur Acad Dermatol Venereol 2011;25 Suppl 3:1-13. [PMID: 21470314 DOI: 10.1111/j.1468-3083.2011.04033.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
151 Leger S, Etienne M, Duval-modeste A, Roussel A, Caron F, Thiberville L. Pneumopathie interstitielle subaiguë après traitement d’un psoriasis par infliximab. Annales de Dermatologie et de Vénéréologie 2011;138:499-503. [DOI: 10.1016/j.annder.2011.01.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
152 Alani A, Ahmad K, Sadlier M, Ramsay B. Malignancy while on biologics in the treatment of psoriasis. A Case series. J Eur Acad Dermatol Venereol 2016;30:693-5. [DOI: 10.1111/jdv.12982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
153 Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J 2016;7:471-80. [PMID: 27990381 DOI: 10.4103/2229-5178.193906] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
154 Richard MA, Barnetche T, Horreau C, Brenaut E, Pouplard C, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maître M, Misery L, Ortonne JP, Paul C. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol 2013;27 Suppl 3:2-11. [PMID: 23845148 DOI: 10.1111/jdv.12162] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
155 Foulkes AC, Grindlay DJC, Griffiths CEM, Warren RB. What’s new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010: What’s new in psoriasis? Clinical and Experimental Dermatology 2011;36:585-9. [DOI: 10.1111/j.1365-2230.2011.04108.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
156 Nasr MW, Jabbour SF, Haber RN, Kechichian EG, El Hachem L. Comparison of microwave ablation, botulinum toxin injection, and liposuction-curettage in the treatment of axillary hyperhidrosis: A systematic review. Journal of Cosmetic and Laser Therapy 2017;19:36-42. [DOI: 10.1080/14764172.2016.1248438] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
157 Paul C, Gallini A, Maza A, Montaudié H, Sbidian E, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, Le Maître M, Misery L, Richard M, Ortonne J. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists: Evidence-based recommendations on conventional systemic treatments. Journal of the European Academy of Dermatology and Venereology 2011;25:2-11. [DOI: 10.1111/j.1468-3083.2011.03990.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
158 Eliasson L, Bewley AP, Mughal F, Johnston KM, Kuznik A, Patel C, Lloyd AJ. Evaluation of psoriasis patients' attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments. Patient Prefer Adherence 2017;11:353-62. [PMID: 28280308 DOI: 10.2147/PPA.S121838] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
159 O’neill I. Efficacy of tumour necrosis factor-α antagonists in aphthous ulceration: review of published individual patient data: TNF-α antagonists in aphthous ulceration. Journal of the European Academy of Dermatology and Venereology 2012;26:231-5. [DOI: 10.1111/j.1468-3083.2011.04041.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
160 Ara M, Pérez A, Ferrando J. Encuesta a dermatólogos sobre terapia biológica en pacientes con psoriasis moderada-grave en España. Actas Dermo-Sifiliográficas 2011;102:706-16. [DOI: 10.1016/j.ad.2011.03.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
161 DeCoster E, Alves de Medeiros A, Bostoen J, Stockman A, van Geel N, Lapeere H, Lambert J. A multileveled approach in psoriasis assessment and follow-up: A proposal for a tailored guide for the dermatological practice. J Dermatolog Treat 2016;27:298-310. [PMID: 26671313 DOI: 10.3109/09546634.2015.1117566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
162 Cordiali-Fei P, Bianchi L, Bonifati C, Trento E, Ruzzetti M, Francesconi F, Bultrini S, D'Agosto G, Bordignon V, Francavilla V, Tripiciano A, Chiricozzi A, Campione E, Cavallotti C, Orlandi A, Berardesca E, Di Carlo A, Chimenti S, Ensoli F. Immunologic biomarkers for clinical and therapeutic management of psoriasis. Mediators Inflamm 2014;2014:236060. [PMID: 25136144 DOI: 10.1155/2014/236060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
163 Hung R, Ungureanu S, Edwards C, Gambles B, Anstey AV. Home phototherapy for psoriasis: a review and update. Clin Exp Dermatol 2015;40:827-33. [DOI: 10.1111/ced.12703] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
164 Campanati A, Diotallevi F, Martina E, Paolinelli M, Radi G, Offidani A. Safety update of etanercept treatment for moderate to severe plaque psoriasis. Expert Opin Drug Saf 2020;19:439-48. [PMID: 32178543 DOI: 10.1080/14740338.2020.1740204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
165 Stiff KM, Glines KR, Porter CL, Cline A, Feldman SR. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Expert Review of Clinical Pharmacology 2018;11:1209-18. [DOI: 10.1080/17512433.2018.1548277] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
166 Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol. 2012;39:269-273. [PMID: 22077677 DOI: 10.1111/j.1346-8138.2011.01434.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
167 Rodríguez-jiménez P, Mir-viladrich I, Chicharro P, Solano-lópez G, López-longo F, Taxonera C, Sánchez-martínez P, Martínez-lacasa X, García-gasalla M, Dorca J, Arias-guillén M, García-garcía J, Dauden E. Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico. Actas Dermo-Sifiliográficas 2018;109:584-601. [DOI: 10.1016/j.ad.2018.03.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
168 Arzpayma P, Jones H, Harper P, Knight V, Shipley D, Edwards C, Anstey A. Creation and assessment of a computerized modelling tool for optimizing planning of home and hospital-based phototherapy. Br J Dermatol 2017;176:1390-1. [DOI: 10.1111/bjd.14994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
169 Griffiths C. Comparing biological therapies in psoriasis: implications for clinical practice: Comparing biological therapies in psoriasis. Journal of the European Academy of Dermatology and Venereology 2010;24:10-4. [DOI: 10.1111/j.1468-3083.2010.03831.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
170 Mahil SK, McSweeney SM, Kloczko E, McGowan B, Barker JN, Smith CH. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic. Br J Dermatol 2019;181:946-53. [PMID: 30729517 DOI: 10.1111/bjd.17741] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
171 Saraceno R, Pietroleonardo L, Mazzotta A, Zangrilli A, Bianchi L, Chimenti S. TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis. Expert Opinion on Biological Therapy 2013;13:469-73. [DOI: 10.1517/14712598.2013.736960] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
172 Bakkour W, Purssell H, Chinoy H, Griffiths C, Warren R. The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. J Eur Acad Dermatol Venereol 2016;30:86-91. [DOI: 10.1111/jdv.12997] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
173 Sozzani S, Abbracchio MP, Annese V, Danese S, De Pità O, De Sarro G, Maione S, Olivieri I, Parodi A, Sarzi-Puttini P. Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity 2014;47:287-306. [PMID: 24697663 DOI: 10.3109/08916934.2014.897333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
174 Basra MKA, Hussain S. Application of the dermatology life quality index in clinical trials of biologics for psoriasis. Chin J Integr Med 2012;18:179-85. [DOI: 10.1007/s11655-012-1007-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
175 Wain T, Choy B, Satchell AC, Woods JA, Frew JW. Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep 2018;4:500-5. [PMID: 29984296 DOI: 10.1016/j.jdcr.2018.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
176 Burden A, Warren R, Kleyn C, Mcelhone K, Smith C, Reynolds N, Ormerod A, Griffiths C; on behalf of the BADBIR Study Group. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives: Development and methodology of BADBIR. British Journal of Dermatology 2012;166:545-54. [DOI: 10.1111/j.1365-2133.2012.10835.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 8.9] [Reference Citation Analysis]
177 O’neill I. Guidance on the use of biological agents in the treatment of oral mucosal disease: Correspondence. British Journal of Dermatology 2010;162:1410-1. [DOI: 10.1111/j.1365-2133.2010.09704.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
178 Mrowietz U, Kragballe K, Reich K, Griffiths CE, Gu Y, Wang Y, Rozzo SJ. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Br J Dermatol 2013;168:374-80. [PMID: 22880843 DOI: 10.1111/j.1365-2133.2012.11214.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
179 Griffiths CEM, Barnes MR, Burden AD, Nestle FO, Reynolds NJ, Smith CH, Warren RB, Barker JNWN, On Behalf Of The Psort Consortium. Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. J Invest Dermatol 2015;135:2903-7. [PMID: 26569580 DOI: 10.1038/jid.2015.286] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
180 Fahim C, Kim BW, Bourcier M, Glassman S, Gooderham M, Guenther L, Gulliver W, Lynde C, Poulin Y, Pratt M, Shear N, Vender R, Walsh S, Fahim S. Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. J Cutan Med Surg 2019;23:282-8. [PMID: 30854878 DOI: 10.1177/1203475419833605] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Bachelez H, van de Kerkhof PCM, Strohal R, Kubanov A, Valenzuela F, Lee J, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. The Lancet 2015;386:552-61. [DOI: 10.1016/s0140-6736(14)62113-9] [Cited by in Crossref: 248] [Cited by in F6Publishing: 87] [Article Influence: 41.3] [Reference Citation Analysis]
182 Norlin JM, Calara PS, Persson U, Schmitt-egenolf M. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy. Journal of Dermatological Treatment 2017;28:500-4. [DOI: 10.1080/09546634.2017.1289147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
183 Kawakami H, Matsumoto Y, Abe N, Katori Y, Takahashi K, Tsuboi R, Okubo Y. Perioperative management of tumor necrosis factor-alpha blocker-treated psoriatic patients: Case reports and review. J Dermatol 2016;43:190-3. [PMID: 26346621 DOI: 10.1111/1346-8138.13047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
184 O’neill I, Scully C. Biologics in oral medicine: principles of use and practical considerations: Biologics use and practical considerations. Oral Diseases 2012;18:525-36. [DOI: 10.1111/j.1601-0825.2012.01919.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
185 Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol 2018;57:1521-32. [DOI: 10.1111/ijd.14072] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
186 Mantovani L, Medaglia M, Piacentini P, Tricca M, Vena GA, Vozza A, Castellino G, Roccia A. Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. Dermatol Ther (Heidelb) 2016;6:151-67. [PMID: 27083437 DOI: 10.1007/s13555-016-0114-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
187 Coates LC, Tillett W, Chandler D, Helliwell PS, Korendowych E, Kyle S, McInnes IB, Oliver S, Ormerod A, Smith C. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford). 2013;52:1754-1757. [PMID: 23887065 DOI: 10.1093/rheumatology/ket187] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
188 de Vries ACQ, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, Spuls PI; Cochrane Skin Group. Interventions for nail psoriasis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd007633.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
189 van Lümig P, Driessen R, Berends M, Boezeman J, van de Kerkhof P, de Jong E. Safety of treatment with biologics for psoriasis in daily practice: 5-year data: 5-year safety of biologics for psoriasis in daily practice. Journal of the European Academy of Dermatology and Venereology 2012;26:283-91. [DOI: 10.1111/j.1468-3083.2011.04044.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
190 Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F. Infection risk associated with anti-TNF-α agents: a review. Expert Opin Drug Saf. 2015;14:571-582. [PMID: 25630559 DOI: 10.1517/14740338.2015.1009036] [Cited by in Crossref: 112] [Cited by in F6Publishing: 98] [Article Influence: 18.7] [Reference Citation Analysis]
191 Warren R, Helliwell P, Chinoy H. Time for a ‘joint’ approach?: Editorial. British Journal of Dermatology 2013;168:683-4. [DOI: 10.1111/bjd.12170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
192 Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res 2014;14:559-68. [PMID: 24820452 DOI: 10.1586/14737167.2014.914437] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
193 Prieto-pérez R, Cabaleiro T, Daudén E, Abad-santos F. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J 2013;13:297-305. [DOI: 10.1038/tpj.2012.53] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
194 Puig L, Carrascosa J, Carretero G, de la Cueva P, Lafuente-urrez R, Belinchón I, Sánchez-regaña M, García-bustínduy M, Ribera M, Alsina M, Ferrándiz C, Fonseca E, García-patos V, Herrera E, López-estebaranz J, Marrón S, Moreno J, Notario J, Rivera R, Rodriguez-cerdeira C, Romero A, Ruiz-villaverde R, Taberner R, Vidal D. Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. Actas Dermo-Sifiliográficas (English Edition) 2013;104:694-709. [DOI: 10.1016/j.adengl.2013.04.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
195 Tan JK, Wolfe BJ, Bulatovic R, Jones EB, Lo AY. Critical appraisal of quality of clinical practice guidelines for treatment of psoriasis vulgaris, 2006-2009. J Invest Dermatol 2010;130:2389-95. [PMID: 20555354 DOI: 10.1038/jid.2010.164] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
196 Blauvelt A, Muram TM, See K, Mallinckrodt CH, Crowley JJ, van de Kerkhof P. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. Journal of Dermatological Treatment 2018;29:220-9. [DOI: 10.1080/09546634.2017.1365114] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
197 Cassano N, Loconsole F, Miracapillo A, Travaglini M, Digiuseppe M, Congedo M, Galluccio A, Buquicchio R, Mastrandrea V, Filieri M, Raho G, Pezza M, Vena G. Treatment of Psoriasis with Different Dosage Regimens of Etanercept: Preliminary Results from the TαRanta Plastic Study Group. Int J Immunopathol Pharmacol 2010;23:797-802. [DOI: 10.1177/039463201002300314] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
198 Dickison P, Swain G, Peek JJ, Smith SD. Itching for answers: Prevalence and severity of pruritus in psoriasis. Australas J Dermatol 2018;59:206-9. [DOI: 10.1111/ajd.12747] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
199 Carrascosa JM, Belinchón I, de-la-Cueva P, Izu R, Luelmo J, Ruiz-Villaverde R. Expert recommendations on treating psoriasis in special circumstances. Actas Dermosifiliogr 2015;106:292-309. [PMID: 25595327 DOI: 10.1016/j.ad.2014.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
200 Chen X, Yang M, Cheng Y, Liu GJ, Zhang M. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 2013;:CD009481. [PMID: 24151011 DOI: 10.1002/14651858.CD009481.pub2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
201 Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage? Exp Dermatol. 2014;23:705-709. [PMID: 24815425 DOI: 10.1111/exd.12437] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
202 Medina-Gil C, Dehesa L, Vega A, Kerdel F. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida. Int J Dermatol 2015;54:846-52. [PMID: 26108266 DOI: 10.1111/ijd.12679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
203 Alorainy M, Alshaya M, Al-Rikabi A, Ayesh M, Alsaif F. Acrodermatitis Continua of Hallopeau with Bone Resorption in an 8-Year-Old Patient: A Case Report. Case Rep Dermatol 2017;9:259-64. [PMID: 29422844 DOI: 10.1159/000485370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
204 Dogra S, Mahajan R. Biologics in pediatric psoriasis - efficacy and safety. Expert Opin Drug Saf 2018;17:9-16. [PMID: 29022425 DOI: 10.1080/14740338.2018.1391787] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
205 Epstein D, Sutton A. Modelling Correlated Clinical Outcomes in Health Technology Appraisal. Value in Health 2011;14:793-9. [DOI: 10.1016/j.jval.2011.04.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
206 Vena GA, Cassano N. The effects of alcohol on the metabolism and toxicology of anti-psoriasis drugs. Expert Opin Drug Metab Toxicol 2012;8:959-72. [PMID: 22594656 DOI: 10.1517/17425255.2012.691166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
207 Ling T, Clayton T, Crawley J, Exton L, Goulden V, Ibbotson S, Mckenna K, Mohd Mustapa M, Rhodes L, Sarkany R, Dawe R, Mchenry P, Hughes J, Griffiths M, Mcdonagh A, Buckley D, Nasr I, Swale V, Duarte Williamson C, Levell N, Leslie T, Mallon E, Wakelin S, Hunasehally P, Cork M, Ungureanu S, Donnelly J, Towers K, Saunders C, Davis R, Brain A, Exton L, Mohd Mustapa M. British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A therapy 2015. Br J Dermatol 2016;174:24-55. [DOI: 10.1111/bjd.14317] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
208 Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics 2014;32:395-409. [PMID: 24469676 DOI: 10.1007/s40273-014-0130-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
209 O’neill I, Scully C. Biologics in oral medicine: ulcerative disorders: Biologics: ulcerative disorders. Oral Dis 2013;19:37-45. [DOI: 10.1111/j.1601-0825.2012.01931.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
210 Saeki H, Terui T, Morita A, Sano S, Imafuku S, Asahina A, Komine M, Etoh T, Igarashi A, Torii H, Abe M, Nakagawa H, Watanabe A, Yotsuyanagi H, Ohtsuki M; Biologics Review Committee of the Japanese Dermatological Association for Psoriasis: Chair: Mamitaro Ohtsuki. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol 2020;47:201-22. [PMID: 31916326 DOI: 10.1111/1346-8138.15196] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
211 Dabouz F, Khemis A, Barbe C, Lahfa M, Maccari F, Chaby G, Beneton N, Boye T, Esteve E, Mahé E, Begon E, Pauwels C, Bernard P, Taieb C, Reguiai Z; Resopso network. Factors associated with successful switching between biologic therapies for the treatment of psoriasis in daily dermatological real-life practice: The Resoswitch study. Dermatol Ther 2019;32:e12789. [PMID: 30488520 DOI: 10.1111/dth.12789] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Khalid JM, Globe G, Fox KM, Chau D, Maguire A, Chiou CF. Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study. BMC Dermatol 2013;13:9. [PMID: 23957883 DOI: 10.1186/1471-5945-13-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
213 van de Kerkhof PC. The relevance of biologics for the treatment of patients with psoriasis. British Journal of Dermatology 2009;161:1213-4. [DOI: 10.1111/j.1365-2133.2009.09499.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
214 Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Peleva E, Pottinger E, Samarasekera EJ, Stoddart J, Strudwicke C, Venning VA, Warren RB, Exton LS, Mohd Mustapa MF. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017;177:628-36. [PMID: 28513835 DOI: 10.1111/bjd.15665] [Cited by in Crossref: 137] [Cited by in F6Publishing: 99] [Article Influence: 45.7] [Reference Citation Analysis]
215 Radfar L, Ahmadabadi RE, Masood F, Scofield RH. Biological therapy and dentistry: a review paper. Oral Surg Oral Med Oral Pathol Oral Radiol 2015;120:594-601. [PMID: 26372436 DOI: 10.1016/j.oooo.2015.07.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
216 De Mozzi P, Alexandroff A, Johnston G. Updates from the British Association of Dermatologists 91st Annual Meeting, 5-7 July 2011, London, U.K.: Updates from the BAD 91st Annual Meeting, 2011. British Journal of Dermatology 2012;167:232-9. [DOI: 10.1111/j.1365-2133.2012.11080.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
217 Galiano Mejías S, Carretero G, Ferrandiz C, Vanaclocha F, Daudén E, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Llamas-Velasco M, Jiménez-Puya R, Mendiola MV, Ruiz-Genao D, Descalzo MA, de la Cueva Dobao P; del grupo Biobadaderm. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry. Actas Dermosifiliogr 2017;108:52-8. [PMID: 27658689 DOI: 10.1016/j.ad.2016.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
218 Conti A, Piaserico S, Gisondi P, Odorici G, Galdo G, Lasagni C, Pellacani G. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatol Ther 2017;30. [PMID: 28547750 DOI: 10.1111/dth.12503] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
219 Garcovich S, Ruggeri A, D'Agostino M, Ardito F, De Simone C, Delogu G, Fadda G. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 2012;26:1572-6. [PMID: 21923840 DOI: 10.1111/j.1468-3083.2011.04220.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
220 Hammad R, Hamdino M, El-Nasser AM, Sobhy A, Eldesoky NA, Mashaal AM, Ali HF. Immunoregulatory complement receptor-1 and leukocyte-associated Ig-like receptor-1 expression on leukocytes in Psoriasis vulgaris. Innate Immun 2020;26:683-92. [PMID: 32731787 DOI: 10.1177/1753425920942570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, Piguet V. Oral fumaric acid esters for psoriasis. Cochrane Database Syst Rev 2015;:CD010497. [PMID: 26258748 DOI: 10.1002/14651858.CD010497.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
222 Young MS, Horn EJ, Cather JC. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Review of Clinical Immunology 2014;7:9-13. [DOI: 10.1586/eci.10.92] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
223 Fragoulakis V, Raptis E, Vitsou E, Maniadakis N. Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece. Clinicoecon Outcomes Res 2015;7:73-83. [PMID: 25609988 DOI: 10.2147/CEOR.S75263] [Reference Citation Analysis]
224 Fabiano A, De Simone C, Gisondi P, Piaserico S, Lasagni C, Pellacani G, Conti A. Management of patients with psoriasis treated with biological drugs needing a surgical treatment. Drug Dev Res 2014;75 Suppl 1:S24-6. [PMID: 25381969 DOI: 10.1002/ddr.21189] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
225 Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1-10. [PMID: 20857129 DOI: 10.1007/s00403-010-1080-1] [Cited by in Crossref: 435] [Cited by in F6Publishing: 370] [Article Influence: 39.5] [Reference Citation Analysis]
226 Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol 2018;45:279-86. [DOI: 10.1111/1346-8138.14096] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
227 Roberts C, Angus JE, Williams HC, Villanueva E, Saeterdal I, Jobling R, Roberts C. Ustekinumab for plaque psoriasis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd008947] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
228 Julià A, Ferrándiz C, Dauden E, Fonseca E, Fernández-lópez E, Sanchez-carazo JL, Vanaclocha F, Puig L, Moreno-ramírez D, Lopez-estebaranz JL, Herrera E, de la Cueva P, Ávila G, Alonso A, Tortosa R, López-lasanta M, Marsal S. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. Pharmacogenomics J 2015;15:322-5. [DOI: 10.1038/tpj.2014.71] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
229 Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011;50:1700-1711. [PMID: 21690185 DOI: 10.1093/rheumatology/ker190] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 9.4] [Reference Citation Analysis]
230 Goetghebeur MM, Wagner M, Nikodem M, Zyla A, Micaleff A, Amzal B. Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study. Ther Innov Regul Sci 2016;50:620-31. [PMID: 30231761 DOI: 10.1177/2168479016642812] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
231 Meyer KC, Decker C, Baughman R. Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. Clin Chest Med 2010;31:565-88. [PMID: 20692548 DOI: 10.1016/j.ccm.2010.05.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
232 Bachelez H, Battistella M. Les recommandations européennes et anglaises sur la place des biothérapies dans le psoriasis modéré à sévère. Annales de Dermatologie et de Vénéréologie 2011;138:H14-7. [DOI: 10.1016/s0151-9638(11)70074-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
233 Iskandar I, Ashcroft D, Warren R, Yiu Z, Mcelhone K, Lunt M, Barker J, Burden A, Ormerod A, Reynolds N, Smith C, Griffiths C. Demographics and disease characteristics of patients with psoriasis enrolled in the B ritish A ssociation of D ermatologists B iologic I nterventions R egister. Br J Dermatol 2015;173:510-8. [DOI: 10.1111/bjd.13908] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 9.7] [Reference Citation Analysis]
234 Chandler DJ, Bewley A. Ustekinumab for the treatment of psoriatic arthritis. Expert Review of Clinical Pharmacology 2014;7:111-21. [DOI: 10.1586/17512433.2014.888310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
235 Basra MK, Chowdhury MM, Smith EV, Freemantle N, Piguet V. A Review of the Use of the Dermatology Life Quality Index as a Criterion in Clinical Guidelines and Health Technology Assessments in Psoriasis and Chronic Hand Eczema. Dermatologic Clinics 2012;30:237-44. [DOI: 10.1016/j.det.2011.11.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
236 Tichy M, Zapletalova J. Experience with the systemic treatment of severe forms of psoriasis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012;156:29-40. [DOI: 10.5507/bp.2012.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
237 Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D. Moderate Psoriasis: A Proposed Definition. Actas Dermosifiliogr 2017;108:911-7. [PMID: 28823420 DOI: 10.1016/j.ad.2017.07.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
238 Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). Am J Clin Dermatol 2017;18:273-80. [PMID: 28074446 DOI: 10.1007/s40257-016-0246-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
239 Almasi-Nasrabadi M, Robati RM, Zargari O, Shahidi-Dadras M. Considerable variation among Iranian dermatologists in the knowledge and attitudes regarding the use of biologic agents to manage psoriasis. Int J Womens Dermatol 2019;5:356-60. [PMID: 31909157 DOI: 10.1016/j.ijwd.2019.09.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 de Eusebio E, Armario-hita JC, de Miquel VA. Treatment of Psoriasis: Focus on Clinic-based Management with Infliximab. Am J Clin Dermatol 2014;15:5-16. [DOI: 10.1007/s40257-013-0054-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
241 Sánchez-moya A, Dauden E. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients: Tuberculosis infection in psoriatic patients on anti-TNF therapy. Journal of the European Academy of Dermatology and Venereology 2011;25:730-3. [DOI: 10.1111/j.1468-3083.2010.03836.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
242 O’neill I. PLENARY ABSTRACT: Biological response modifiers in inflammatory oral mucosal disease. Oral Diseases 2010;16:514-5. [DOI: 10.1111/j.1601-0825.2010.01753.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
243 Augustin M, Alvaro-gracia J, Bagot M, Hillmann O, van de Kerkhof P, Kobelt G, Maccarone M, Naldi L, Schellekens H. A framework for improving the quality of care for people with psoriasis: Improving care for people with psoriasis. Journal of the European Academy of Dermatology and Venereology 2012;26:1-16. [DOI: 10.1111/j.1468-3083.2012.04576.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
244 Böncüoğlu E, Kıymet E, Şahinkaya Ş, Akaslan Kara A, Çağlar İ, Arıkan KÖ, Gülfidan G, Bayram N, Devrim İ. Usefulness of screening tests for diagnosis of latent tuberculosis infection in children. Pediatr Pulmonol 2021;56:1114-20. [PMID: 33200565 DOI: 10.1002/ppul.25173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Gottlieb AB, Greb JE, Goldminz AM. Psoriasis Trends and Practice Gaps. Dermatologic Clinics 2016;34:235-42. [DOI: 10.1016/j.det.2016.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
246 Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, Costanzo A, Conti A, Dapavo P, De Simone C. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774-790. [PMID: 28244153 DOI: 10.1111/jdv.14114] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 18.3] [Reference Citation Analysis]
247 Puig L, Daudén E, Carrascosa J. Comentarios a las directrices europeas y británicas sobre el tratamiento de la psoriasis. Actas Dermo-Sifiliográficas 2010;101:285-90. [DOI: 10.1016/j.ad.2009.12.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
248 Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat 2018;29:569-78. [PMID: 29532693 DOI: 10.1080/09546634.2017.1422591] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 19.0] [Reference Citation Analysis]
249 Gupta MA, Gupta AK. Current concepts in psychodermatology. Curr Psychiatry Rep 2014;16:449. [PMID: 24740235 DOI: 10.1007/s11920-014-0449-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
250 van Lümig P, Driessen R, Roelofs-thijssen M, Boezeman J, van de Kerkhof P, de Jong E. Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab: Laboratory monitoring in patients with psoriasis on biologics. British Journal of Dermatology 2011;165:375-82. [DOI: 10.1111/j.1365-2133.2011.10329.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
251 Gupta MA, Gupta AK, Knapp K. Dissatisfaction with cutaneous body image is directly correlated with insomnia severity: A prospective study in a non-clinical sample. Journal of Dermatological Treatment 2014;26:193-7. [DOI: 10.3109/09546634.2014.883060] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
252 Rencz F, Poór AK, Péntek M, Holló P, Kárpáti S, Gulácsi L, Szegedi A, Remenyik É, Hidvégi B, Herszényi K, Jókai H, Beretzky Z, Brodszky V. A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions. J Eur Acad Dermatol Venereol 2018;32:783-90. [PMID: 29114942 DOI: 10.1111/jdv.14676] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
253 Bito T, Nishikawa R, Hatakeyama M, Kikusawa A, Kanki H, Nagai H, Sarayama Y, Ikeda T, Yoshizaki H, Seto H, Adachi A, Horikawa T, Oka M, Nishigori C. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br J Dermatol 2014;170:922-9. [PMID: 24329764 DOI: 10.1111/bjd.12791] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
254 Singh TP, Lee CH, Farber JM. Chemokine receptors in psoriasis. Expert Opinion on Therapeutic Targets 2013;17:1405-22. [DOI: 10.1517/14728222.2013.838220] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
255 Peleva E, Exton L, Kelley K, Kleyn C, Mason K, Smith C. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol 2018;178:103-13. [DOI: 10.1111/bjd.15830] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
256 Llamas-velasco M, de la Cueva P, Notario J, Martínez-pilar L, Martorell A, Moreno-ramírez D. Moderate Psoriasis: A Proposed Definition. Actas Dermo-Sifiliográficas (English Edition) 2017;108:911-7. [DOI: 10.1016/j.adengl.2017.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
257 Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011;71:1733-53. [PMID: 21902296 DOI: 10.2165/11207530-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
258 Youn SW, Kim BR, Lee JH, Song HJ, Choe YB, Choi JH, Kim NI, Kim KJ, Youn JI. Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report. Ann Dermatol 2015;27:184-9. [PMID: 25834358 DOI: 10.5021/ad.2015.27.2.184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
259 Matsumoto K, Kurasawa T, Yoshimoto K, Suzuki K, Takeuchi T. Identification of neutrophil β2-integrin LFA-1 as a potential mechanistic biomarker in ANCA-associated vasculitis via microarray and validation analyses. Arthritis Res Ther 2021;23:136. [PMID: 33957974 DOI: 10.1186/s13075-021-02510-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Downs AM. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab. Br J Dermatol 2010;163:433-4. [PMID: 20456344 DOI: 10.1111/j.1365-2133.2010.09832.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
261 Belinchón I, Ramos J, Carretero G, Ferrándiz C, Rivera R, Daudén E, De la Cueva-dobao P, Gómez-garcía F, Herrera-ceballos E, Sánchez-carazo J, López-estebaranz J, Alsina M, Ferrán M, Torrado R, Carrascosa J, Llamas-velasco M, Ortiz P, García-doval I, Descalzo M; The Biobadaderm Study Group. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. J Eur Acad Dermatol Venereol 2017;31:1700-8. [DOI: 10.1111/jdv.14314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
262 Wechter T, Cline A, Feldman SR. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manag 2018;14:1489-97. [PMID: 30174431 DOI: 10.2147/TCRM.S177127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]